Zheng Quan Zhi Xing·2025-07-15 16:30Core Points - The report indicates that Wang Haibo has reduced his shareholding in Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. from 5.41% to 5.00%, marking the first time his holding has fallen below 5% [1][4] - The reduction was executed through centralized bidding, with a total of 4,270,722 shares sold, representing 0.41% of the company's total share capital [4][8] - The purpose of this share reduction is attributed to Wang Haibo's personal funding needs, as stated in the previously announced reduction plan [3][4] Summary by Sections Section 1: Definition - The report defines key terms, including the information disclosure obligor (Wang Haibo) and the company (Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd.) [2] Section 2: Information Disclosure Obligor - Wang Haibo is identified as the information disclosure obligor, with no other significant shareholdings in other listed companies [3] Section 3: Purpose of Equity Change - The equity change is primarily driven by Wang Haibo's funding needs, as outlined in a prior announcement regarding the reduction plan [3][4] Section 4: Method of Equity Change - Prior to the equity change, Wang Haibo held 56,099,327 shares (5.41% of total shares). After the reduction, he holds 51,828,605 shares (5.00%) [4][6] - The shares were sold between July 14 and July 15, 2025, through centralized bidding [4][8] Section 5: Trading History - There were no other transactions involving the company's shares by Wang Haibo in the six months preceding the report [5][8] Section 6: Other Significant Matters - The report confirms that all relevant information regarding the equity change has been disclosed accurately and completely [6][8]